A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GNE-131 | GNE-131 is a potent and selective hNaV1.7 inhibitor with IC50 of 3 nM. Synonyms: GNE 131; GNE131. Grade: 98% by HPLC. CAS No. 1629063-81-5. Molecular formula: C23H30N4O3S. Mole weight: 442.6. |  |
| GNE-131 | GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1629063-81-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-112279. |  |
| GNE-140 racemate | GNE-140 racemate is the racemate of GNE-140, a potent lactate dehydrogenase A (LDHA) inhibitor. Synonyms: GNE-140 (racemate). Grade: 98% by HPLC. CAS No. 1802977-61-2. Molecular formula: C25H23ClN2O3S2. Mole weight: 499.0. | |
| GNE-140 racemate | GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1802977-61-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100742. | |
| GNE-1858 | GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor. Grade: 99%. CAS No. 2680616-96-8. Molecular formula: C21H26F2N8. Mole weight: 428.48. | |
| GNE-207 | GNE-207 is a potent, selective and orally bioavailable inhibitor of the bromodomain of CBP, with an IC50 of 1 nM, exhibits a selectively index of >2500-fold against BRD4 (1). GNE-207 shows excellent CBP potency, with an EC50 of 18 nM for MYC expression in MV-4-11 cells[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2158266-58-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120028. | |
| GNE 220 | GNE 220 is a potent and selective MAP4K4 inhibitor with an IC50 of 7 nM. Synonyms: GNE-220; GNE220. CAS No. 1199590-75-4. Molecular formula: C25H26N8. Mole weight: 438.54. | |
| GNE 220 hydrochloride | GNE 220 is a potent and selective MAP4K4 inhibitor with an IC50 of 7 nM. Grade: 98%. CAS No. 2448286-21-1. Molecular formula: C25H27ClN8. Mole weight: 474.99. | |
| GNE 220 hydrochloride | GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4, with an IC50 of 7 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 2448286-21-1. Pack Sizes: 5 mg; 10 mg; 25 mg. Product ID: HY-U00428A. | |
| GNE-2256 | GNE-2256 (molecule 19), a chemical probe, is an orally active IRAK4 (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 Ki=1.4 nM; IL-6 IC50=190 nM)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2102170-43-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-148238. | |
| GNE-272 | GNE-272 is a potent and selective CBP/EP300 inhibitor with IC50s of 0.02, 0.03, 0.41 and 13 μM for CBP, EP300, BRET and BRD4, respectively. It shows significant antiproliferative effects in hematologic cancer cell lines and modulates MYC expression in vivo, corresponding to antitumor activity in AML tumor models. It is also a selective in vivo probe for the Bromodomains of CBP/EP300. Synonyms: (S)-1-(3-((2-fluoro-4-(1-methyl-1h-pyrazol-4-yl)phenyl)amino)-1-(tetrahydrofuran-3-yl)-1,4,6,7-tetrahydro-5h-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one; N-[2-Fluoro-4-(1-methyl-1H-pyrazole-4-yl)phenyl]-1-[(S)-tetrahydrofuran-3beta-yl]-5-acetyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-amine; 1-(3-{[2-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]amino}-1-[(3S)-oxolan-3-yl]-1H,4H,5H,6H,7H-pyrazolo[4,3-c]pyridin-5-yl)ethan-1-one. Grade: ≥95%. CAS No. 1936428-93-1. Molecular formula: C22H25FN6O2. Mole weight: 424.47. | |
| GNE-272 | GNE-272 is a potent and selective CBP/EP300 inhibitor with IC50 values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1936428-93-1. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100726. | |
| GNE-274 | GNE-274, a non-degrader structurally related to GDC-0927 (ER degrader), does not induce ER turnover and acts as a partial ER agonist in breast cancer cell lines. It increases chromatin accessibility of ER-DNA binding sites, while GDAC-0927 does not. It is a potent ER ligand-binding domain (LBD) inhibitor and can be used for the study of cancer. Synonyms: 2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)-. CAS No. 2369048-69-9. Molecular formula: C29H31NO4. Mole weight: 457.56. | |
| GNE 2861 | GNE-2861 is a potent and selective inhibitor of the group 2 p21-activated kinases (PAKs; IC50s = 7.5, 126, and 36 nM for PAK4, -5, and -6, respectively). Synonyms: 1-[2-[1-(2-Amino-4-pyrimidinyl)-2-[(2-methoxyethyl)amino]-1H-benzimidazol-6-yl]ethynyl]cyclohexanol; 1-[2-[3-(2-aminopyrimidin-4-yl)-2-(2-methoxyethylamino)benzimidazol-5-yl]ethynyl]cyclohexan-1-ol. Grade: ≥98% by HPLC. CAS No. 1394121-05-1. Molecular formula: C22H26N6O2. Mole weight: 406.48. | |
| GNE 2861 | GNE 2861 is a PAK inhibitor that displays group II selectivity. GNE 2861 inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1394121-05-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12632. | |
| GNE-317 | GNE-317 is a potent and selective PI3K inhibitor with potential anticncer activity. GNE-317 targets the PI3K pathway and can cross the Blood-Brain Barrier. GNE-317 was identified as having physicochemical properties predictive of low efflux by P-gp and BCRP. Studies in transfected MDCK cells showed that GNE-317 was not a substrate of either transporter. GNE-317 markedly inhibited the PI3K pathway in mouse brain, causing 40% to 90% suppression of the pAkt and pS6 signals up to 6-hour postdose. GNE-317 was efficacious in the U87, GS2, and GBM10 orthotopic models, achieving tumor growth inhibition of 90% and 50%, and survival benefit, respectively. GNE-317 could be effective in the treatment of GBM. Synonyms: GNE-317; GNE 317; GNE317. Grade: >98%. CAS No. 1394076-92-6. Molecular formula: C19H22N6O3S. Mole weight: 414.48. | |
| GNE-3500 | GNE-3500 has been found to be a Retinoic acid receptor-related Orphan receptor C agonist that could be probably significant in studies of some inflammatory diseases. Synonyms: GNE-3500; GNE 3500; GNE3500; 1-(4-(3-fluoro-4-(((3S,6R)-3-methyl-1,1-dioxido-6-phenyl-1,2-thiazinan-2-yl)methyl)phenyl)piperazin-1-yl)ethan-1-one. Grade: 98%. CAS No. 1537859-24-7. Molecular formula: C24H30FN3O3S. Mole weight: 459.58. | |
| GNE-3511 | GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1496581-76-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12947. | |
| GNE-3511 | GNE-3511 has been found to be a DLK, MAP3K12 kinase inhibitor that could probably exhibit protection action of primary neurons. IC50: 0.107 uM (DLK). Synonyms: GNE-3511; GNE 3511; GNE3511. CHEMBL3393333; SCHEMBL15602439; BDBM50059190; 2-[[6-(3,3-difluoropyrrolidin-1-yl)-4-[1-(oxetan-3-yl)piperidin-4-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile. Grade: 98%. CAS No. 1496581-76-0. Molecular formula: C23H26F2N6O. Mole weight: 440.50. | |
| GNE-371 | GNE-371 is a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like, with an IC50 of 10 nM for TAF1(2). Uses: Scientific research. Category: Signaling pathways. CAS No. 1926986-36-8. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112803. | |
| GNE-477 | GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor with IC50 of 4 nM for PI3Kα and Kiapp of 21 nM for mTOR. Synonyms: GNE-477, GNE477, GNE 477. Grade: >98%. CAS No. 1032754-81-6. Molecular formula: C21H28N8O3S2. Mole weight: 504.63. | |
| GNE-490 | GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC50=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1033739-92-2. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-10812. | |
| GNE-493 | GNE-493 is a potent, selective, and orally available dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/12/16/16/32 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ/mTOR respectively. Synonyms: GNE493; GNE-493; GNE 493. Grade: >98%. CAS No. 1033735-94-2. Molecular formula: C17H20N6O2S. Mole weight: 372.44. | |
| GNE-495 | GNE-495 is a Selective MAP4K4 (Mitogen-activated protein kinase kinase kinase kinase 4) Inhibitor. IC50 value is 3.7 nM. GNE-495 shows excellent potency and good PK In vivo. GNE-495 was used to demonstrate in vivo efficacy in a retinal angiogenesis model recapitulating effects that are observed in the inducible Map4k4 knockout mice. Synonyms: GNE-495; GNE 495; GNE495. 8-amino-N-(1-(cyclopropanecarbonyl)azetidin-3-yl)-2-(3-fluorophenyl)-1,7-naphthyridine-5-carboxamide. Grade: 98%. CAS No. 1449277-10-4. Molecular formula: C22H20FN5O2. Mole weight: 405.43. | |
| GNE-495 | GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1449277-10-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100343. | |
| GNE-4997 | GNE-4997, a pyrazol derivative, has been found to be an ITK inhibitor that could have significant biological activities. Ki: 0.09 nM. Synonyms: GNE-4997; GNE-4997; GNE-4997; (4aS,5aR)-N-(1-((R)-((R)-1,1-dioxidotetrahydro-2H-thiopyran-2-yl)(phenyl)methyl)-1H-pyrazol-4-yl)-5,5-difluoro-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f]indazole-3-carboxamide. Grade: 98%. CAS No. 1705602-02-3. Molecular formula: C25H27F2N5O3S. Mole weight: 515.58. | |
| GNE-616 | GNE-616 is a potent selective inhibitor of Nav1.7, with potential for the treatment of chronic pain. Synonyms: GNE616. Grade: 98%. CAS No. 2349371-81-7. Molecular formula: C24H23F4N5O3S. Mole weight: 537.53. | |
| GNE-617 | GNE-617 is a novel and specific Nampt inhibitor with an IC50 of 18.9 nM in A549 cell. Synonyms: GNE-617; GNE 617; GNE617. Grade: >98%. CAS No. 1362154-70-8. Molecular formula: C21H15F2N3O3S. Mole weight: 427.42. | |
| GNE-617 | GNE-617 Inhibitor. Uses: Scientific use. Product Category: T4335. CAS No. 1362154-70-8. |  |
| GNE-617 | GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer. Uses: Scientific research. Category: Signaling pathways. CAS No. 1362154-70-8. Pack Sizes: 10 mM * 1 mL in DMSO; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15766. | |
| GNE-618 | GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1362151-42-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12628. | |
| GNE-6468 | GNE-6468, an imidazopyrimidine derivative, has been found to be a RORc inverse agonist that could be more effective than other members and be significant in studying the biological activities of RORC. Synonyms: GNE-6468; GNE 6468; GNE6468; 4-(6-(2-chloro-6-cyclopropylbenzoyl)imidazo[1,5-a]pyrimidin-8-yl)-2-hydroxybenzoic acid. Grade: 98%. CAS No. 1677668-27-7. Molecular formula: C23H16ClN3O4. Mole weight: 433.85. | |
| GNE-6468 | GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC50 value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC50 of 30 nM for IL-17 PBMC[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1677668-27-7. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-19775. | |
| GNE-6640 | GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 (USP7), with IC50 values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP47 and Ub-MDM2, respectively[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2009273-67-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112937. | |
| GNE-6776 | GNE-6776 is a selective and orally bioavailable USP7 inhibitor[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2009273-71-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107986. | |
| GNE-6776 | GNE-6776 is a potent and non-covalent USP7 inhibitor with IC50 of 1.34 uM. GNE-6776 targets cellular USP7, MDM2, and p53 signalling pathways, and induces tumor cell death. Synonyms: GNE 6776; GNE-6776; GNE6776; 5-[6-amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridyl]-N-methyl-pyridine-2-carboxamide. Grade: 98%. CAS No. 2009273-71-4. Molecular formula: C20H20N4O2. Mole weight: 348.406. | |
| GNE684 | GNE684 is a potent inhibitor of potent receptor interacting protein 1 (RIP1). Synonyms: (s)-N-((s)-7-methoxy-1-methyl-2-oxo-2,3,4,5-tetrahydro-1h-pyrido[3,4-b]azepin-3-yl)-5-phenyl-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazole-2-carboxamide. Molecular formula: C23H24N6O3. Mole weight: 432.48. | |
| GNE 6901 | GNE 6901 (compound 40) is a potent GluN2A-selective NMDAR positive allosteric modulator (PAM) with an EC50 of 382 nM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1698900-69-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg. Product ID: HY-107423. | |
| GNE-781 | GNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1936422-33-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108696. | |
| GNE-781 | GNE-781 is a potent, selective and orally active bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein (CBP). GNE-781 exhibits antitumor activity in an AML tumor model and was also shown to decrease Foxp3 transcript levels in a dose dependent manner. Synonyms: GNE 781; GNE781. CAS No. 1936422-33-1. Molecular formula: C27H33F2N7O2. Mole weight: 525.59. | |
| GNE-7883 | GNE-7883 is a pan-TEAD inhibitor that blocks the association of YAP/TAZ with TEAD. GNE-7883 effectively reduces chromatin accessibility at TEAD motifs, inhibits cell proliferation in multiple cell line models, and achieves strong anti-tumor efficacy in vivo. In addition, GNE-7883 effectively overcomes intrinsic and acquired resistance to KRAS (Kirsten rat sarcoma viral oncogene homolog) G12C inhibitors in multiple preclinical models by inhibiting YAP/TAZ activation[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2648450-42-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-147214. | |
| GNE-7915 | GNE-7915 is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM. Synonyms: GNE7915; GNE 7915; GNE-7915. CAS No. 1351761-44-8. Molecular formula: C19H21F4N5O3. Mole weight: 443.403. | |
| GNE-7915 tosylate | GNE-7915 tosylate is a potent, selective and brain-penetrant LRRK2 inhibitor with an IC50 of 9 nM. Synonyms: (4-{[4-(Ethylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino}-2-fluoro-5-methoxyphenyl)(4-morpholinyl)methanone 4-methylbenzenesulfonate (1:1); Methanone, [4-[[4-(ethylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-2-fluoro-5-methoxyphenyl]-4-morpholinyl-, 4-methylbenzenesulfonate (1:1). Grade: ≥95%. CAS No. 2070015-00-6. Molecular formula: C26H29F4N5O6S. Mole weight: 615.60. | |
| GNE-8505 | GNE-8505 is an orally available dual leucine zipper kinase (DLK) inhibitor. Synonyms: example 152 [WO2014111496]. CAS No. 1620573-48-9. Molecular formula: C21H24F3N5O. Mole weight: 419.44. | |
| GNE-8505 | GNE-8505 is an orally active, blood-brain barrier-permeable selective dual leucine zipper kinase (DLK) inhibitor. GNE-8505 has an IC50 of 0.144 μM for pJNK, and EC50 of 0.457 μM for DRG. GNE-8505 inhibits the DLK/JNK pathway, reduces stress-induced c-Jun phosphorylation levels, decreases neuronal death and suppresses axonal degeneration. GNE-8505 reduces phosphorylated c-Jun levels in the retina, spinal cord and brain tissues of mice. GNE-8505 is applicable to research related to Alzheimer's disease and amyotrophic lateral sclerosis (ALS)[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1620573-48-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-114332. | |
| GNE-8525 | This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor efficacy in tumor xenograft model derived from the KM12 cell line. TRKA are believed to be the key oncogenic driver in many tumors including glioblastoma, melanoma and so on. Uses: Antitumor. Synonyms: GNF-8625; GNF 8625; GNF8625. (R)-1-(6-(6-(2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)-[2,4'-bipyridin]-2'-yl)piperidin-4-ol. Grade: 98%. CAS No. 1196546-33-4. Molecular formula: C31H30FN7O. Mole weight: 535.63. | |
| GNE-900 | GNE-900 is an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor. In combination with chemotherapeutic agents, GNE-900 sustains ATR/ATM signaling, enhances DNA damage, and induces apoptotic cell death. GNE-900 has little single-agent activity in the absence of chemotherapy and does not grossly potentiate the cytotoxicity of gemcitabine in normal bone marrow cells. In vivo scheduling studies show that optimal administration of the ChK1 inhibitor requires a defined lag between gemcitabine and GNE-900 administration. Synonyms: GNE900; GNE 900; 3-(4-(Piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile; 6-cyano-3-(4-piperidin-1-ylmethyl-phenyl)-9H-dipyrido[2,3-b; 4',3'-d]pyrrole. Grade: 98%. CAS No. 1200126-26-6. Molecular formula: C23H21N5. Mole weight: 367.45. | |
| GNE 9278 | GNE 9278 is a positive allosteric modulator of NMDA receptors. GNE-9278 targets transmembrane domain (TMD) extracellular surface of agonist-bound NMDARs, stabilizing NMDARs in an activated state by slowing L-L-glu & gly off-rate. Synonyms: Benzenesulfonamide, 4-cyclohexyl-N-(1,7-dihydro-5-methyl-7-oxo-2-propyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-; GNE-9278; GNE9278; 4-cyclohexyl-N-(5-methyl-7-oxo-2-propyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)benzenesulfonamide. Grade: ≥98% by HPLC. CAS No. 2315311-83-0. Molecular formula: C21H27N5O3S. Mole weight: 429.54. | |
| GNE-955 | GNE-955 is a potent and orally active pan Pim kinase inhibitor, with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively. Synonyms: (S)-1-(3-methoxy-6-(6-(6-methylpyrazin-2-yl)-1H-pyrazolo[4,3-c]pyridin-1-yl)pyridin-2-yl)piperidin-3-amine. CAS No. 1527523-39-2. Molecular formula: C22H24N8O. Mole weight: 416.48. | |
| GNE-9605 | GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC50 value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) [1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1536200-31-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg. Product ID: HY-12282. | |
| GNE-9605 | GNE-9605 retained excellent predicted human metabolic stability when assayed in human liver microsomes and hepatocytes. In addition, no reversible or time-dependent inhibition of any of the major CYP isoforms was observed. The demonstrated metabolic stability, brain penetration across multiple species, and selectivity of these inhibitors support their use in preclinical efficacy and safety studies. Synonyms: GNE9605; GNE-9605; GNE 9605. Grade: 0.98. CAS No. 1536200-31-3. Molecular formula: C17H20ClF4N7O. Mole weight: 449.839. | |
| GNE-9815 | GNE-9815 is one of the most highly kinase-selective RAF inhibitors targeting KRAS mutant cancers via combination treatment. Synonyms: GNE9815; GNE 9815. CAS No. 2729996-45-4. Molecular formula: C26H22FN5O2. Mole weight: 455.48. | |
| GNE-9822 | GNE-9822, a pyrazole derivative, has been found to be a ITK inhibitor that could probably be effective in studies of some inflammatory disorders. Synonyms: GNE-9822; GNE 9822; GNE9822; (S)-N-[1-[3-(Dimethylamino)-1-phenylpropyl]-1H-pyrazol-4-yl]-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-carboxamide. Grade: 98%. CAS No. 1557232-32-2. Molecular formula: C24H32N6O. Mole weight: 420.56. | |
| GNE-9822 | GNE-9822 is a potent, orally active and selective ITK inhibitor with a Ki value of 0.7 nM, and an EC50 value of 354.5 nM. GNE-9822 has good ADME properties. GNE-9822 can be used in research of asthma[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1557232-32-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-12410. | |
| GNE-987 | GNE-987 is a VHL-dependent BRD4 PROTAC degrader. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC50=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50=4.7 and 4.4 nM, respectively). GNE-987 can be used for the research of cancer[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2417371-71-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-129937A. | |
| GNE-987 | GNE-987, a PROTAC connected by ligands for von Hippel-Lindau and BRD4, is used in PROTAC-Antibody Conjugate (PAC). GNE-987 shows picomolar activity of cell BRD4 degradation (DC50 = 0.03 nM for EOL-1 AML cell line), and binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50s = 4.7 and 4.4 nM, respectively). It combines a potent BET binder/inhibitor, a VHL binding fragment and a 10 methylene spacer moiety. Synonyms: 7-(3,5-Difluoropyridin-2-yl)-N-(11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)-2-methyl-10-((methylsulfonyl)methyl)-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulene-9-carboxamide; N-[11-({7-(3,5-Difluoropyridin-2-yl)-2-methyl-10-[(methylsulfonyl)methyl]-3-oxo-3,4,6,7-tetrahydro-2H-2,4,7-triazadibenzo[cd,f]azulene-9-carbonyl}amino)undecanoyl]-3-methyl-L-valyl-(4R)-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-L-prolinamide. Grade: ≥98%. CAS No. 2417371-71-0. Molecular formula: C56H67F2N9O8S2. Mole weight: 1096.31. | |
| GNE-987 GSH linker-1 | GNE-987 GSH linker-1, a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 (HY-129937A) and disulfide-containing linker. GNE-987 GSH linker-1 remains inactive as a degrader until intracellular release of GNE-987 via disulfide reduction and linker self-immolation. GNE-987 GSH linker-1 can be used for the research of acute myeloid leukemia[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2417370-39-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-129938. | |
| Gnetol | Gnetol is a phenolic compound isolated from the root of Gnetum montanum. Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 86361-55-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-126052. | |
| GNF1331 | GNF1331 is a potent, selective and orally bioavailable porcupine (PORCN) inhibitor with IC50 value of 12 nM. It plays a critical role in multiple cancers, such as cutaneous squamous cell carcinoma (SCC), colorectal cancer and breast cancer. Uses: Gnf1331 plays a critical role in multiple cancers, such as cutaneous squamous cell carcinoma (scc), colorectal cancer and breast cancer. Synonyms: N-(6-methoxy-1,3-benzothiazol-2-yl)-2-[(4-propyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide; GNF-1331; GNF 1331; GNF1331. Grade: 98%. CAS No. 603101-22-0. Molecular formula: C20H20N6O2S2. Mole weight: 440.54. | |
| GNF179 | GNF179 is an optimized 8,8-dimethyl imidazolopiperazine analog that exhibits antimalarial potency (IC50 of 4.8 nM against the multidrug resistant strain W2). GNF179 is orally active[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1261114-01-5. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15975. | |
| GNF179 | GNF179 exhibits a low clearance (CL=22 ml/min/kg, ~25% of hepatic blood flow in mice), a large volume of distribution (steady-state volume of distribution, Vss=11.8 l/kg), a moderate residence time (MRT=9 hours) and suitable terminal half-life (t1/2=8.9 hours). GNF179 reduced Plasmodium berghei parasitemia levels by 99.7% with a single 100 mg/kg oral dose, and prolonged mouse survival by an average of 19 days. GNF179 was able to protect against an infectious P. berghei sporozoite challenge with a single oral dose at 15 mg/kg while NITD609 was not. Synonyms: GNF 179; GNF-179. Grade: >98%. CAS No. 1261114-01-5. Molecular formula: C22H23ClFN5O. Mole weight: 427.9. | |
| GNF179 Metabolite | GNF179 exhibits a low clearance (CL=22 ml/min/kg, ~25% of hepatic blood flow in mice), a large volume of distribution (steady-state volume of distribution, Vss=11.8 l/kg), a moderate residence time (MRT=9 hours) and suitable terminal half-life (t1/2=8.9 hours). GNF179 reduced Plasmodium berghei parasitemia levels by 99.7% with a single 100 mg/kg oral dose, and prolonged mouse survival by an average of 19 days. GNF179 was able to protect against an infectious P. berghei sporozoite challenge with a single oral dose at 15 mg/kg while NITD609 was not. Synonyms: GNF 179 Metabolite; GNF-179 Metabolite. Grade: >98%. CAS No. 1310455-86-7. Molecular formula: C14H16FN3. Mole weight: 245.3. | |
| GNF179 Metabolite-13C2 | GNF179 Metabolite-13C2. Grade: > 95%. Molecular formula: C12H16FN3[13C]2. Mole weight: 247.28. | |
| GNF 2 | GNF 2. Group: Biochemicals. Grades: Purified. CAS No. 778270-11-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GNF-2 | GNF-2 is a Bcr-Abl inhibitor that binds to the myristoyl binding pocket, an allosteric site distant from the active site, stabilizing the inactive form of the kinase. Thus, it can selectively inhibit Bcr-Abl phosphorylation (IC50 = 267 nM) without affecting native c-Abl or a panel of 63 additional kinases. Synonyms: GNF2; GNF-2; GNF 2. Grade: 98.73%. CAS No. 778270-11-4. Molecular formula: C18H13F3N4O2. Mole weight: 374.32. | |
| GNF2133 | GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 μM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2561414-56-8. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-142295. | |
| GNF351 | GNF351 is a potent antagonist of aryl hydrocarbon receptor (AHR). GNF351 is capable of competing with the photoaffinity ligand for binding to the human AHR and has a relative affinity for the AHR similar to that of SR1. CAS No. 1227634-69-6. Molecular formula: C24H25N7. Mole weight: 411.50. | |
| GNF351 | GNF351 is a full aryl hydrocarbon receptor (AHR) antagonist. GNF351 competes with a photoaffinity AHR ligand for binding to the AHR with an IC50 of 62 nM. GNF351 is minimal toxicity in mouse or human keratinocytes[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1227634-69-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-102023. | |
| GNF362 | GNF362 is a selective, potent, and orally bioavailable inhibitor of inositol trisphosphate 3 kinase B (Itpkb) with an IC50 of 9 nM. GNF362 also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. Inositol trisphosphate 3 kinase B (Itpkb) is a Ca2+-dependent kinase, which phosphorylates the 3 position of Ins (1,4,5) P3 to generate inositol 1,3,4,5-tetrakisphosphate [Ins (1,3,4,5) P4][1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1003019-41-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126750. | |
| GNF4877 | GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6?nM and 16?nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC50 of 0.66?μM for mouse β (R7T1) cells)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2041073-22-5. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-129492. | |
Our database is helping our users find suppliers everyday.
